Evidence map›Paper›PMID 28428542›Full record

ArticleScientific reports2017

Poly-protein G-expressing bacteria enhance the sensitivity of immunoassays.

Wen-Rui Hao, Michael Chen, Yi-Jou Chen, Yu-Cheng Su, Chiu-Min Cheng, Hsiang-Yin Hsueh, An-Pei Kao, Yuan-Chin Hsieh, Johny Chang, Ming-Yang Tseng and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Wen-Rui HaoDivision of Cardiovascular Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Michael ChenPh.D. program for the Clinical Drug Discovery from Botanical Herbs, Taipei Medical University, Taipei, Taiwan.
Yi-Jou ChenPh.D. program for the Clinical Drug Discovery from Botanical Herbs, Taipei Medical University, Taipei, Taiwan.
Yu-Cheng SuInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Chiu-Min ChengDepartment of Aquaculture, National Kaohsiung Marine University, Kaohsiung, Taiwan.
Hsiang-Yin HsuehSchool of Pharmacy, Taipei Medical University, Taipei, Taiwan.
An-Pei KaoStemforce Biotechnology Co., Ltd, Chiayi City, Taiwan.
Yuan-Chin HsiehGraduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Johny ChangGraduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan.
Ming-Yang TsengGraduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Kuo-Hsiang ChuangPh.D. program for the Clinical Drug Discovery from Botanical Herbs, Taipei Medical University, Taipei, Taiwan. khchuang@tmu.edu.tw.
Taipei Medical University · TWKaohsiung Medical University · TWInstitute of Biomedical Sciences, Academia Sinica · TWNational Kaohsiung Marine University · TWTaipei Medical University-Shuang Ho Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sensitivities of solid-phase immunoassays are limited by the quantity of detection antibodies bound to their antigens on the solid phase. Here, we developed a poly-protein G-expressing bacterium as an antibody-trapping microparticle to enhance the signals of immunoassays by increasing the accumulation of detection antibodies on the given antigen. Eight tandemly repeated fragment crystallisable (Fc) binding domains of protein G were stably expressed on the surface of Escherichia coli BL21 cells (termed BL21/8G). BL21/8G cells showed a higher avidity for trapping antibodies on their surface than monomeric protein G-expressing BL21 (BL21/1G) cells did. In the sandwich enzyme-linked immunosorbent assay (ELISA), simply mixing the detection antibody with BL21/8G provided a detection limit of 6 pg/mL for human interferon-α (IFN-α) and a limit of 30 pg/mL for polyethylene glycol (PEG)-conjugated IFN-α (Pegasys), which are better than that of the traditional ELISA (30 pg/mL for IFN-α and 100 pg/mL for Pegasys). Moreover, the sensitivity of the Western blot for low-abundance Pegasys (0.4 ng/well) was increased by 25 folds upon mixing of an anti-PEG antibody with BL21/8G cells. By simply being mixed with a detection antibody, the poly-protein G-expressing bacteria can provide a new method to sensitively detect low-abundance target molecules in solid-phase immunoassays.

Indexed as

Antibodies, MonoclonalAntigens, BacterialBinding SitesEnhancer Elements, GeneticEnzyme-Linked Immunosorbent AssayEscherichia coliHumansInterferon-gammaLimit of DetectionAntibodies, MonoclonalAntigens, BacterialIFNG protein, humanInterferon-gamma

Identifiers

PMID28428542
PMCPMC5430508
OpenAlexW2606237596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.